Antitrypsin treatment

 Antitrypsin treatment,To antitrypsin how treatment

Added to the anti-trypsin treatment (augmentation therapy): aims to increase the liver endogenous α1-antitrypsin release thereby increasing the anti-elastase activity to reduce liver damage reduce the lung damage, but this method also increased the α1 anti-trypsincombination of protease and serum protease complex receptors stimulate the abnormal α1-antitrypsin products to increase the lead to its accumulation in the liver cells, thereby increasing the damage to the liver, so this method is not suitable for the treatment of α1-antitrypsin deficiency liver disease

Liver transplantation for the treatment progressed to late-α1-antitrypsin deficiency liver disease in patients with this disease for liver transplantation in the treatment of the most common metabolic liver disease, liver transplantation, one addition to the alternative has been damage to the liver can also be corrected metabolic defects so that the progress to systemic disease

α1-antitrypsin deficiency liver disease is considered to be one of the normal genotype of many diseases, its potential benefits can be reduced for liver transplantation in the demand for α1-antitrypsin deficiency liver gene therapy by gene therapy to rebuild is on α1 α1-AT-AT deficiency liver cell genome added to the normal α1-AT gene so that cells can synthesize normal in addition to other treatments already carried out studies such as the development of serum proteasome blockers (serping-enzyme complex receptor, blocker) is used to reduce the abnormal α1-AT production or block the endoplasmic reticulum α1-AT binding sites in order to avoid effectively to abnormal secretion of α1-AT is the forefront of treatment research

protease inhibitor | antitrypsin | Terms & Conditions          Copyright © Healthgen Biotechnology Co., Ltd. All Rights Reserved.